About US
Contact us
-
Novartis partners with Civica Rx to ease hospital shortages for 6 high-demand generic injectablesThe COVID-19 pandemic and its drain on key drugs used in acute care has put an enormous strain on hospitals in desperate need of medicines for their patients. In a move to shore up chronic shortages2020/7/7
-
EU in 'constructive' talks with Gilead to nab remdesivir amid U.S. supply grab: reportWhen it comes to pandemic drug supply, it’s every country for itself. That’s the message the rest of the world got from the Trump administration’s deal to lockup almost all doses of Gilead Sciences’2020/7/6
-
Bayer hits Roundup settlement snag as judge 'tentatively inclined' to reject $1.25B dealLooks like Bayer’s Roundup litigation headache may not be over after all, even after the company committed nearly $11 billion to a settlement. U.S. District Judge Vince Chhabria, who oversees the cla2020/7/6
-
Novavax inks $1.6B Warp Speed deal to fund COVID vaccine's phase 3 testing, manufacturingNovavax and its COVID-19 shot are racing against well-funded global pharmaceutical players, but a new deal with the U.S. government will push the biotech's fundraising haul past $2 billion. The Maryl2020/7/3
-
Regeneron bags $450M deal with U.S. government for coronavirus antibody cocktail supplyAmong the drugmakers seeking an answer for COVID-19, Regeneron once showed promise in its quest to repurpose an older therapy as a treatment and develop a novel antibody cocktail, too. Now, thanks to2020/7/3
-
J&J expands COVID-19 vaccine pact with Catalent for finishing work at Italian facilityJohnson & Johnson has been on a manufacturing deal spree as it nears human trials for its COVID-19 vaccine hopeful. On the same day it inked a $480 million order from a Maryland CDMO, J&J ann2020/7/2
-
CureVac scores $85M loan to scale COVID-19 shot manufacturing at German siteGerman vaccine maker CureVac recently raised eyebrows for its reported work with electric car maker Tesla to produce mobile mRNA printers to help scale production of a COVID-19 shot. Now, the company2020/7/2
-
Sanofi, Regeneron shut down Kevzara trial in COVID-19 after finding no benefit for ventilated patientsIn the early days of the COVID-19 pandemic, Sanofi and Regeneron launched an ambitious plan to try out rheumatoid arthritis med Kevzara in desperately ill patients. But after early warning signs, a p2020/7/1
-
J&J sews up 5 years of coronavirus vaccine supply in $480M-plus deal with EmergentJohnson & Johnson, like all drugmakers in the COVID-19 vaccine race, is hoping to cobble together enough manufacturing capacity to rapidly scale production of its shot hopeful. Now, to the tune o2020/7/1
-
Gilead to start testing inhaled remdesivir, eyeing earlier COVID-19 useGilead Sciences’ infused antiviral remdesivir currently holds an FDA emergency use authorization to treat severe hospitalized COVID-19 patients. But the company is hoping a new formulation could get2020/6/24